Global Examples of Therapeutic Area Registries

Published on 22/12/2025

Therapeutic Area Registries Around the World: Practical Examples for Real-World Evidence

Therapeutic area registries are pivotal tools for tracking real-world treatment outcomes, understanding disease progression, and supporting regulatory decisions. Around the globe, registries have been established in diverse therapeutic domains—from oncology and cardiology to rare and autoimmune diseases. This guide showcases global examples of therapeutic area registries, providing pharma and clinical trial professionals with actionable insights into structure, success factors, and real-world evidence (RWE) contributions.

Table of Contents

Why Therapeutic Registries Matter:

Unlike clinical trials, therapeutic registries reflect broad patient populations, treatment heterogeneity, and healthcare system variations. They help:

Assess long-term treatment effectiveness and safety
Identify unmet needs in patient care
Support market access and reimbursement decisions
Fulfill post-marketing regulatory obligations

Well-designed registries often align with pharma regulatory compliance expectations and can even act as external control arms for clinical studies.

1. Cardiovascular Registries:

Example: SWEDEHEART (Sweden)

Focus: Acute coronary syndromes, heart failure, and interventions
Scope: National registry linking hospitals, labs, and pharmacies
Impact: Improved adherence to guidelines and reduced mortality

SWEDEHEART demonstrates how integrated EHR-based data collection and continuous quality feedback can transform outcomes.

2. Oncology Registries:

Example: SEER Program (United States)

Focus: Cancer incidence, survival, treatment trends
Scope: Covers 48% of the U.S. population across multiple states
Impact: Enables survival trend analysis

and population-based outcome research

SEER data is frequently used to inform GMP audit checklist-aligned pharmacovigilance programs and comparative effectiveness research.

3. Autoimmune Disease Registries:

Example: British Society for Rheumatology Biologics Register (BSRBR)

Focus: Safety and effectiveness of biologic therapies in rheumatoid arthritis
Scope: More than 20,000 patients enrolled in the UK
Impact: Helped identify infection and malignancy risks linked to biologics

The BSRBR registry supports long-term risk-benefit profiling of immune-modulating therapies and aligns with principles seen on StabilityStudies.in.

4. Diabetes Registries:

Example: DPV Initiative (Germany)

Focus: Pediatric and adult patients with type 1 and type 2 diabetes
Scope: Multinational data from over 400 centers in Europe
Impact: Improved glycemic control, therapy standardization, and benchmarking

DPV exemplifies how structured data collection combined with feedback to providers can drive measurable care improvements.

5. Rare Disease Registries:

Example: Cystic Fibrosis Foundation Patient Registry (CFFPR – USA)

Focus: Tracking health outcomes in cystic fibrosis (CF)
Scope: >30,000 patients across 130 accredited care centers
Impact: Data used to support FDA approvals and improve median life expectancy

Rare disease registries are essential when randomized trials are infeasible. They require adherence to equipment qualification for data systems due to their regulatory utility.

6. Neurological Disease Registries:

Example: MSBase (Global)

Focus: Long-term outcomes in multiple sclerosis (MS)
Scope: Over 70,000 patients in 40+ countries
Impact: Enables global tracking of treatment switches, relapses, and disability progression

MSBase uses a harmonized data model and governance framework to allow cross-border data sharing.

7. Orthopedic and Surgical Registries:

Example: Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR)

Focus: Joint replacement outcomes and device surveillance
Scope: Nationwide registry capturing >98% of all procedures
Impact: Identified underperforming implants and led to regulatory actions

This registry supports proactive safety signal detection and aligns with post-market surveillance requirements set by TGA.

8. Pediatric Registries:

Example: PEDSnet (United States)

Focus: Learning health system for pediatric populations
Scope: Data from eight children’s hospitals across the U.S.
Impact: Accelerated observational studies, registry-based trials, and QI programs

PEDSnet uses standardized terminologies and centralized governance to ensure reproducibility and security.

Lessons from Global Registries:

Strong governance: Define oversight boards, publication policies, and data access rules
Data interoperability: Use HL7 FHIR, CDISC, and MedDRA standards
Electronic systems: Ensure systems are validated for security and auditability, per SOP training pharma guidelines
Participant engagement: Transparency and feedback loops improve retention
Multistakeholder collaboration: Involve payers, regulators, clinicians, and patients

How to Apply These Models to New Registries:

Pharma professionals launching new registries can take inspiration from global examples by:

Defining precise therapeutic and geographic scope
Benchmarking data elements and follow-up intervals
Incorporating quality-of-life and adherence metrics
Establishing shared governance with local investigators
Aligning with real-world regulatory standards and practices

Conclusion:

Therapeutic area registries from around the world offer practical blueprints for successful real-world evidence generation. By understanding how global leaders structure and sustain their registries, pharma professionals can design programs that not only meet scientific and regulatory expectations but also drive lasting improvements in patient care. Whether tracking rare diseases or chronic conditions, registries remain foundational to data-driven healthcare decisions across the globe.